These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 32212489)

  • 1. [Predictive factors for clinically significant elevation of post-prostatectomy Gleason score in patients with biopsy Gleason score ≤7].
    Guo X; Ma LM; Wu Y; Zhang YP; Li HL; Nong SJ; Guan YB; Huang YQ; Cai B
    Zhonghua Nan Ke Xue; 2018 Dec; 24(12):1094-1099. PubMed ID: 32212489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Associations of pretreatment serum total testosterone measurements with pathology-detected Gleason score cancer.
    Porcaro AB; Petrozziello A; Ghimenton C; Migliorini F; Sava T; Caruso B; Romano M; Cavalleri S; Artibani W
    Urol Int; 2014; 93(3):269-78. PubMed ID: 24334919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.
    Corcoran NM; Casey RG; Hong MK; Pedersen J; Connolly S; Peters J; Harewood L; Gleave ME; Costello AJ; Hovens CM; Goldenberg SL
    BJU Int; 2012 Jul; 110(1):36-42. PubMed ID: 22085203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Significance of the Disparity Between Biopsy and Pathologic Gleason Score After Radical Prostatectomy in Clinical Candidates for Active Surveillance According to the Royal Marsden Criteria.
    Jo JK; Hong SK; Byun SS; Lee SE; Lee S; Oh JJ
    Clin Genitourin Cancer; 2016 Aug; 14(4):e329-33. PubMed ID: 26935997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum total testosterone is a significant preoperative variable independently contributing to separating the prostate cancer population into prostatectomy Gleason score groups.
    Porcaro AB; Petrozziello A; Ghimenton C; Migliorini F; Sava T; Caruso B; Cocco C; Romano M; Cavalleri S; Artibani W
    Urol Int; 2013; 91(1):55-61. PubMed ID: 23751412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigative clinical study on prostate cancer part IX and X: estradiol and the pituitary-testicular-prostate axis at the time of initial diagnosis and subsequent cluster selection of the patient population after radical prostatectomy.
    Porcaro AB; Ghimenton C; Petrozziello A; Sava T; Migliorini F; Romano M; Caruso B; Cocco C; Antoniolli SZ; Lacola V; Rubilotta E; Monaco C
    Anticancer Res; 2012 Oct; 32(10):4523-32. PubMed ID: 23060581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High Testosterone Preoperative Plasma Levels Independently Predict Biopsy Gleason Score Upgrading in Men with Prostate Cancer Undergoing Radical Prostatectomy.
    Porcaro AB; Petroziello A; Brunelli M; De Luyk N; Cacciamani G; Corsi P; Sebben M; Tafuri A; Tamanini I; Caruso B; Ghimenton C; Monaco C; Artibani W
    Urol Int; 2016; 96(4):470-8. PubMed ID: 26845458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate-specific antigen vs prostate-specific antigen density as a predictor of upgrading in men diagnosed with Gleason 6 prostate cancer by contemporary multicore prostate biopsy.
    Oh JJ; Hong SK; Lee JK; Lee BK; Lee S; Kwon OS; Byun SS; Lee SE
    BJU Int; 2012 Dec; 110(11 Pt B):E494-9. PubMed ID: 22540236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is the biopsy Gleason score important in predicting outcomes for patients after radical prostatectomy once the pathological Gleason score is known?
    Vira MA; Guzzo T; Heitjan DF; Tomaszewski JE; D'Amico A; Wein AJ; Malkowicz SB
    BJU Int; 2008 May; 101(10):1232-6. PubMed ID: 18419697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Along the pituitary-testis-prostate axis, serum total testosterone is a significant preoperative variable independently contributing to separating the prostate cancer population into prostatectomy Gleason score groups.
    Porcaro AB; Petrozziello A; Ghimenton C; Migliorini F; Sava T; Caruso B; Cocco C; Romano M; Artibani W
    Anticancer Res; 2012 Nov; 32(11):5015-22. PubMed ID: 23155273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extended prostate biopsy scheme improves reliability of Gleason grading: implications for radiotherapy patients.
    King CR; McNeal JE; Gill H; Presti JC
    Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):386-91. PubMed ID: 15145152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of extraprostatic extension in patients with clinically organ-confined prostate cancer.
    Lin S; Zhang Q; Li P; Li Z; Sun Y; Shao Y; Zhang X; Fu S
    Urol Int; 2014; 92(3):282-8. PubMed ID: 24280781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concordance between biopsy and radical prostatectomy specimen Gleason score in internal and external pathology facilities.
    Grasso AA; Cozzi G; Palumbo C; Albo G; Rocco B
    Anticancer Res; 2014 Oct; 34(10):5585-8. PubMed ID: 25275059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gleason score concordance on biopsy-confirmed prostate cancer: is pathological re-evaluation necessary prior to radical prostatectomy?
    Truesdale MD; Cheetham PJ; Turk AT; Sartori S; Hruby GW; Dinneen EP; Benson MC; Badani KK
    BJU Int; 2011 Mar; 107(5):749-754. PubMed ID: 20840549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Risk factors of ISUP Modified Gleason score upgrading after radical prostatectomy].
    Li XD; Qu GY; Xu N; Xue XY; Wei Y; Zheng QS; Li JF; Cai H; Lin YZ
    Zhonghua Nan Ke Xue; 2016 May; 22(5):415-9. PubMed ID: 27416665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive Factors and Oncologic Outcome of Downgrade to Pathologic Gleason Score 6⁻7 after Radical Prostatectomy in Patients with Biopsy Gleason Score 8⁻10.
    Chung DY; Lee JS; Goh HJ; Koh DH; Kim MS; Jang WS; Choi YD
    J Clin Med; 2019 Mar; 8(4):. PubMed ID: 30935044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of clinical outcomes between upgraded pathologic Gleason score 3 + 4 and non-upgraded 3 + 4 prostate cancer among patients who are candidates for active surveillance.
    Jo JK; Hong SK; Byun SS; Lee SE; Oh JJ
    World J Urol; 2015 Nov; 33(11):1729-34. PubMed ID: 25809876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of extraprostatic cancer by prostate specific antigen density, endorectal MRI, and biopsy Gleason score in clinically localized prostate cancer.
    Horiguchi A; Nakashima J; Horiguchi Y; Nakagawa K; Oya M; Ohigashi T; Marumo K; Murai M
    Prostate; 2003 Jun; 56(1):23-9. PubMed ID: 12746843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Follicle-stimulating hormone and the pituitary-testicular-prostate axis at the time of initial diagnosis of prostate cancer and subsequent cluster selection of the patient population undergoing standard radical prostatectomy.
    Porcaro AB; Migliorini F; Petrozziello A; Sava T; Romano M; Caruso B; Cocco C; Ghimenton C; Zecchinini Antoniolli S; Lacola V; Rubilotta E; Monaco C; Comunale L
    Urol Int; 2013; 90(1):45-55. PubMed ID: 23128438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Surgical strategy selection and experience summary of prostate cancer with positive single needle biopsy].
    Hao YC; Yan Y; Zhang F; Qiu M; Zhou L; Liu K; Lu J; Xiao CL; Huang Y; Liu C; Ma LL
    Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Aug; 52(4):625-631. PubMed ID: 32773790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.